Kornimate/medical-research-clean huggingface dataset:
association between heat pain detection threshold and area of secondary hyperalgesia

Conditions: Healthy

Summary: the purpose of this prospective study is to investigate how close heat pain detection threshold is associated with the area of secondary hyperalgesia, elicited by the clinical pain model brief thermal sensitization. furthermore we wish to investigate how close the clinical pain model: pain during 1 min. heating of the skin (45 degrees celsius), and the psychological tests, pain catastrophizing scale and hospital anxiety and depression scale are associated with the area of secondary hyperalgesia, elicited by the clinical pain model brief thermal sensitization.

the study participants will be tested with 3 types of clinical pain models on two separate identical study days. a minimum of 7 days will separate the two study days, thus, the minimum length of the study is 7 days, but can be higher. the 3 types of pain conditioning consist of 1) brief thermal sensitisation (bts), 2) heat pain detection threshold (hpdt), and pain during 1 min. thermal stimulation (p-ts. the order of the stimulations (hpdt and bts) is randomised for each patient and each study day, by a random allocation sequence, computer-generated by copenhagen trial unit and stored in sealed and opaque envelopes to secure adequate allocation concealment. p-ts is conducted subsequent to bts and hpdt. the participants will complete the psychological tests pain catastrophizing scale (pcs) and hospital anxiety and depression scale (hads) in their private home prior to study day 1. the completed tests will be placed in opaque sealed envelopes to secure blinding of the investigator and outcome assessor.

Eligibility criteria:
inclusion criteria: * age \>18 years and \<35 years * speak and understand danish * male gender * study participants who have understood and signed the informed consent * no prescription medicine during the last 30 days. exclusion criteria: * study participants that cannot cooperate to the test. * study participants who have a weekly intake of \>21 units of alcohol, or a have consumed \>3 units of alcohol within 24 hours before experimental day. * study participants with a substance abuse, assessed by the investigator. * study participants, who have consumed analgesics less than 3 days before experimental day. * study participants, who have consumed antihistamines less than 48 hours before experimental day. * study participants, who have consumed antidepressant medication during the last 30 days before experimental day. * study participants with chronic pain. * study participants with neurological illnesses. * study participants with psychiatric diagnoses. * study participants with tattoos on the extremities. * study participants with eczema, wounds or sunburns on the sites of stimulation. * study participants with a body mass index of \>30 kg/m2 or \<18 kg/m2

Keywords: experimental pain men
intraoperative chemotherapy against hepatocellular carcinoma recurrence

Conditions: Hepatocellular Carcinoma

Summary: hepatectomy is still the most important treatment for hcc.high recurrence rate mostly influence it's prognosis, especially for the patient with tumor \>5cm, multiple tumor and who cannot accept r0 resection.our retrospective study showed sustained released 5-fu implanted into the liver incisal margin after tumor was resected could reduce the recurrence rate of hcc after liver resection.according to this, we proceed this rct to prospectively observe the effect of sustained released 5-fu,and we also want to know whether combined with sustained released cisplatin will get better effect in preventing the tumor recurrence,especially in short time after liver resection.

150 hcc patients with tumor \>5cm, multiple tumor and who cannot accept r0 resection will be randomized divided into 3 groups. group a (50 cases) will be implanted 600mg sustained released 5-fu into liver incisal margin after tumor is resected. group b (50 cases) will be implanted 600mg sustained released 5-fu and 60mg sustained released cisplatin. group c (50 cases) will be the controlled one which will not be implanted any chemotherapeutic drugs. all patients will accepted tace 30 days after liver resection. we will follow up all patients until they are dead or missed connected. related adverse reaction will be recorded. total survival time (tst) and disease free survival time (dfst) will be calculated too. at the end of the study we will compare the difference of adverse reaction, complication, tst and dfst between the 3 groups. according to the result we will estimate these drugs' antitumor effect and safety.

Eligibility criteria:
inclusion criteria: 1. tumor \>5cm; 2. multiple tumor located in one liver lobe; 3. margin of tumor is not clear; 4. cutting edge to tumor \<1cm; 5. portal vein branch invasion; 6. without extra-liver metastasis; 7. patient's liver function and condition is able to accept hepatectomy. exclusion criteria: 1. single tumor \<=5cm; 2. multiple tumor located more than in one liver lobe; 3. margin of tumor is clear; 4. cutting edge to tumor \>=1cm; 5. portal vein stem invasion 6. extra-liver metastasis; 7. patient's liver function and condition cannot accept hepatectomy.

Keywords: hepatocellular carcinoma liver resection intraoperative chemotherapy
metabolic adaptations to diabetes in african americans

Conditions: Diabetes

Summary: we do not know why diabetic patients cannot protect themselves against low blood sugar. therefore, in this study, we will perform a comprehensive assessment of the body's response to low blood sugar by measuring changes in blood hormones, blood sugar production, and nerve signals.

morning and afternoon hypoglycemic episodes of 70, 60, or 50 mg/dl produce increased blunting of subsequent counterregulation dependent upon the depth of preceding hypoglycemia. we wanted to test this hypothesis in healthy african american individuals to determine if there is a difference in their responses to varying depths of hypoglycemia.

Eligibility criteria:
inclusion criteria: * healthy males and females aged 18-40 yrs with no family history of diabetes mellitus. * all prospective volunteers will have routine blood tests to screen for biochemical, hormonal and hematological abnormalities. * female volunteers will also undergo an hcg urine pregnancy test. exclusion criteria: * prior or current history of poor health * abnormal results following blood and physical examination * pregnancy

Keywords: hypoglycemia african americans
[11c]donepezil pet for imaging the autonomous nervous system in parkinsons disease

Conditions: Parkinson's Disease

Summary: aim: investigate wether there are differences in the parasympathetic nervous system in parkinsons patients compared to controls. materials and methods: we use the tracer \[11c\]donepezil to image the parasympathetic nervous system. the investigators will include 20 parkinsons patients and 20 healthy controls aged 40-80 in our study. the participants will receive a careful medical examination, including a neurological examination, as part of the inclusion process. the subjects also have an mri scan of the brain. then pet/ct scans with \[11c\]donepezil are conducted - once for the upper abdominal region and once for the head region. for evaluating the function of the parasympathetic nervous system gastric emptying time, heart rate variability and salivary flow will be measured. these measureless will be correlated to the pet findings. perspectives: the study will potentially result in the development of a pet ligand for imaging the parasympathetic nervous system. this will have applications for research in parkinson's disease, diabetes, heart disease and other disorders, in which the autonomic nervous system is involved


Eligibility criteria:
inclusion criteria: * age 40-80 years exclusion criteria: * dementia, * psychiatric diseases, * serious medical illness including any type of previous cancer * any drug with known interaction with the autonomic nervous system * metal in the body (because of mri scan) * pregnancy or breast feeding (because of radiation due to pet/ct) * known diseases of the salivary glands, stomach, intestines. * prior major surgery to salivary glands, esophagus, stomach.
brain small chain fatty acid metabolism in parkinson disease: ketones

Conditions: Parkinson Disease; Lewy Body Dementia; Parkinson Disease Dementia

Summary: small exploratory open-label pilot study to assess supplementation of a ketone ester (ketoneaid) as a potential therapy for persons with parkinson disease (pd), parkinson disease dementia/lewy body dementia (pdd/lbd), and healthy controls.

the overarching goal of this study is to investigate glucose metabolic, cognitive, clinical and imaging changes in persons with pd and pdd/lbd before and after a month supplementation of a ketone ester (ketoneaid) in a small open label exploratory clinical trial. positive findings in this small exploratory pilot trial may support future target engagement studies of ketone supplementation in pd and normal adults.

Eligibility criteria:
inclusion criteria: * healthy control volunteers over 45 years of age * people with parkinson disease over 45 years of age * people with parkinson's disease dementia or lewy body dementia over 45 years of age exclusion criteria: * participants with contra-indications to mr imaging, including pacemakers or claustrophobia; * evidence of large vessel stroke or mass lesion on mri * regular use of anti-cholinergic, benzodiazepines, high dose (\>100mg qd) of quetiapine, or neuroleptic drugs * history of significant gi disease * significant metabolic or uncontrolled medical comorbidity * poorly controlled diabetes * pregnancy or breast feeding * current excessive alcohol use * suicidal ideation

Keywords: ketone ester ketosis functional neuroimaging
improving work ability of young adults with stroke

Conditions: Stroke

Summary: this project will investigate effects of a novel theory-driven 6-week virtual personal resource building and inclusive volunteering intervention (pvi) on young stroke survivors' work ability, self-efficacy and psychosocial outcomes. it is hypothesised that participants in the intervention group, compared with the control group, will demonstrate the outcomes below at immediately and 3 months post-intervention with respect to baseline: 1) significant improvement in work ability (primary outcome), 2) significant improvements in self-efficacy, health-related quality of life (hrqol), emotional well-being and social skills (secondary outcomes). eligible participants will be randomly assigned to receive usual care or pvi with usual care and the control group participants will receive usual stroke care services.

returning to work is a major rehabilitation priority for young stroke survivors. this project will investigate effects of a novel theory-driven 6-week virtual personal resource building and inclusive volunteering intervention (pvi) on young stroke survivors' work ability, self-efficacy and psychosocial outcomes. a 2-arm, assessor-blind, randomised controlled trial will be conducted. eligible participants will be randomly assigned to receive usual care or pvi with usual care and the control group participants will receive usual stroke care services. outcomes including work ability, self-efficacy, health-related quality of life, emotional well-being and social skills will be measured at baseline, immediately post-pvi and 3 months post-pvi.

Eligibility criteria:
inclusion criteria: * 18-64 years old, * been clinically diagnosed with a first-ever or recurrent ischaemic or haemorrhagic stroke, * living at home, * montreal cognitive assessment score \>2nd percentile, * a modified rankin scale of 4 or below (moderately severe disability), * able to communicate in cantonese and read traditional chinese, * a regular paid employment at the time of stroke, * been unemployed for at least 3 months at the time of recruitment. exclusion criteria: * have been diagnosed with transient ischaemic attack, * have experienced cerebrovascular events due to tumours, * have been diagnosed with a mental condition such as depression, schizophrenia or bipolar disorder, * demonstrate incomprehensible speech or difficulty in comprehending conversations, or * have or are receiving vocational programmes.

Keywords: return to work
evaluation of the novel therapeutic hepatitis b virus synthetic long peptide vaccination isa104

Conditions: Chronic Hepatitis b

Summary: the goal of this clinical trial is to test isa104 in patients with chronic hepatitis b. the main question\[s\] it aims to answer are: * how safe is isa104? * does isa104 induce immunity against hepatitis b virus? different doses of the vaccine isa104 will be administered to participants. these participants are chronic hbv patients being actively treated with antiviral drugs. researchers will compare the isa104 vaccine to a placebo.


Eligibility criteria:
inclusion criteria: * chbv * active treatment with nucs and hbv dna \< limit of quantification exclusion criteria: * immune-compromised * evidence of liver cirrhosis

Keywords: immunotherapy therapeutic vaccination hepatitis b cure
prospective, randomized clinical trial comparing macular photocoagulation with or without intravitreal bevacizumab or triamcinolone for the treatment of diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: purpose: to compare the effects of macular photocoagulation with or without intravitreal bevacizumab (ivb) or triamcinolone (ivta) for the treatment of diabetic macular edema (dme). casuistic and methods: 58 eyes of 44 patients with diffuse dme were randomized to receive either ivb + focal/grid laser (ivb-laser, n=19), ivta + focal/grid laser (ivta-laser, n=16) or focal/grid laser alone (laser, n=23). ophthalmic evaluation, including best-corrected visual acuity (bcva), intraocular pressure (iop) and central macular thickness (cmt) were performed at baseline and monthly for 12 months.


Eligibility criteria:
inclusion criteria: 1. clinically significant diabetic macular edema (dme) with diffuse leakage involving the center of the fovea, with dme greater than 275 microns in oct examination 2. bcva between 0.3 logmar (logarithm of smaller angle of visual resolution) (20/40) and 1.6 logmar (20/800) 3. signed of inform consent. exclusion criteria: 1. hba1c levels greater than 10% 2. thromboembolic event history (including myocardial infarction and stroke) 3. vitreo-macular traction on oct 4. coagulation disorders 5. macular ischemia on fluorescein angiography examination 6. proliferative diabetic retinopathy that required treatment 7. eye surgery 8. history of ocular hypertension or glaucoma 9. any ocular pathology which in the opinion of the investigator, could macular edema or change the visual acuity during the study period (for example, retinal vascular occlusion, uveitis or other inflammatory eye disease, neovascular glaucoma) 10. systemic corticosteroid therapy 11. any conditions that could affect the documentation 12. any previous treatment for diabetic macular edema.

Keywords: diabetic retinopathy macular edema anti-vegf triamcinolone
mental health care provision for adults with intellectual disability and a mental disorder

Conditions: Mental Disorder; Intellectual Disability

Summary: quality of mental health services provision for adults with intellectual disability and comorbid mental disorder is considered inadequate and therefore in need of further improvement. however, empirical findings on this topic are rather scarce. the mementa-study therefore aims to compare mild and moderate intellectual disabled adults with a comorbid mental disorder to mild and moderate intellectual disabled adults who do not have a comorbid mental disorder with respect to clinical parameters. the mementa-study is an observational, epidemiological, cross-sectional study. a representative sample of the target population is realised by the assessment of approximately n=600 intellectual disabled adults working at specialized facilities (sheltered workshops). a cluster sampling with probability proportional to institution and size (n of overall employed persons) will be followed by a simple random sampling of persons of these clustered facilities. a number of parameters such as severity of mental health impairment, needs for care, quality of life (qol), caregiver burden, health services utilization, and costs for care will be assessed by using a set of well-established standardised instruments. quality of mental health care will be assessed and examined by open questions to intellectual disabled adults with a comorbid mental disorder as well as informal caregivers and staff of caring institutions.


Eligibility criteria:
inclusion criteria: * mild or moderate intellectual disability * adults aged between 18-65 years

Keywords: intellectual disability mental disorder dual diagnosis provision needs assessment quality of life
glivec in ph positive lymphoblastic leukemia

Conditions: Acute Lymphoblastic Leukemia; Cromosome Philadelphia Positive

Summary: % positive ph lla with rc alter the glivec and induction chemotherapy treatment

pilot phase ii clinical trial, prospective, multicentric and opened

Eligibility criteria:
inclusion criteria: * new diagnosis lla ph+ (bcr/abl) patients ≤ 65 years old * fertile age women must do a pregnancy test in the 7 days previous at the beginning of clinical trial medication * performance status 0-2 (appendix b); is allowed performance status \> 2 because of lla * patients without organ alteration: hepatic function: global bilirubin, ast, alt, gamma-gt and alkaline phosphatase less than 2 times lsn; renal function: creatinine \ 60 ml/min; anormal renal function caused by lla ; normal heart function (appendix b): fev \> 50%; no chronic respiratory illness. if the anormal values are secondary of the experimental illness the investigator can decide himself if the patient can be included at the clinical trial. * negative hiv serology * written, oral or with witness informed consent. in patients \< 18 years old must be signed written and legal representative informed consent. * no experimental chemotherapy or other experimental treatment. allowed to begin induction chemotherapy from the diagnosis to confirm ph. no major surgical process in the previous 14 days of the treatment start. exclusion criteria: * other lla variability * previous history of coronary valvular, hypertensive cardiopathy illness * chronic hepatic illness * chronic respiratory insufficiency * renal insufficiency not caused by lla * severe neurological problems not caused by lla * severe affection of the performance status (grade 3-4 oms gradation) not caused by lla * pregnancy and women * blastic crisis lmc

Keywords: acute lymphoblastic leukemia
rectal misoprostol in women undergoing myomectomy for intraoperative blood loss: a randomized placebo-controlled study

Conditions: Misoprostol, Blood Loss, Myomectomy

Summary: comparison of efficacy of rectal misoprostol for reduction amount of blood loss in women undergoing myomectomy, both open and laparoscopic approach

according to development of reproductive technology to assist infertile women, rate of myomectomy increases. during this operation, surgeons would deal with hypervascular masses with raw surfaces that tend to bleeding. interventions to diminish bleeding were studied such as using misoprostol, vasopressin, transamenic acid along with mechanical intervention such as tourniquet and uterine artery ligation. but in rajavithi hospital, such procedures aren't generally used because of fewer cases and also lacks of supporting data. misoprostol, used in gynecologic patients for a long time with a wide safety margin acts at prostaglandin receptors of myometrium to stimulate contraction that constricts uterine vessels that lead to decreasing amount of bleeding during the operation. this led to the experimental study of rectal misoprostol administered at 15 - 30 minutes prior the operation to decrease blood loss and also blood transfusion rates. our study also gather data about adverse effect that subject experienced after drug administration.

Eligibility criteria:
inclusion criteria: * patient provisionally diagnosed with leiomyoma of uterus with less than 10 cm diameter * patient undergoing myomectomy, both open and laparoscopic approach * patient aged 25 - 50 years * patient able to give free and informed consent and who agrees to participate bu signing the consent form * patient able to speak and understand thai * patient able to complete the questionnaire exclusion criteria: * patient who was pathologically diagnosed apart from leiomyoma * patient with leiomyoma figo type 0 * patient who has medical conditions that increase bleeding tendency, such as thrombocytopenia, coagulopathy, renal insufficiency, uncontrolled diabetes mellitus, taking antiplatelets or anticoagulants less than 7 days prior the surgery * patient who takes prostaglandin analogs and/or antagonists (nsaids) less than 7 days prior the surgery. * patient who may take higher risks of misoprostol adverse effect such as hypertension, ischemic heart disease, glaucoma, asthma * patient who had and allergic reaction to misoprostol or vitamin b6
evaluation of muscle ischemia in arterial claudication (tsingtao)

Conditions: Peripheral Arterial Disease

Summary: the goal is to compare the results observed in patients that had both an exercise oximetry and a thallium scintigraphy for lower limb claudication

on our routine pratice, patients suffering claudication (specifically atypical claudication or claudication of doubful vascular origin) have exercise oximetry to prove the vascular origin of pain. if still doubtful (inconsistency of pain and oximetry results) patients are referred for thallium scintigraphy. our goal is to compare the results issued from these two test

Eligibility criteria:
inclusion criteria: * claudication suspected of arterial origin exclusion criteria: * missing endopoint value
digital application usage for adherence of patients undergoing robotic assisted radical prostatectomy following oncological and postoperative functional outcomes

Conditions: the Focus of This Study is to Develop an Application for Postoperative Follow-up of Patients With Prostate Cancer

Summary: prostate cancer (pc) is the most common non-skin tumor in men and the second leading cause of death from cancer in brazil. it accounts for 13.8% of deaths from cancer in males, similar to what happens with breast cancer in females, corresponding to 15.8% of cancer deaths in women. mobile applications, software developed for smartphones and tablets used for many different purposes (games, communication, entertainment etc) have become important tools of mhealth (mobile health in portuguese - mobile health) as they allow remote support to patients or self-promotion of health care. it has been used globally to assist in the treatment and control of various diseases such as diabetes, physical inactivity, and many others. in oncology there are several applications developed to assist in the monitoring and treatment of various cancers such as gastric and breast cancer. so far it has not developed an application for follow-up of patients with pc, to capture data on satisfaction of post-treatment patient regarding the comorbidity of surgery, and also loyalty and adherence of patients to follow-up in offices allowing a possible intervention it is done at the right time. nor was made compared to assess whether there is benefit in using this application. thus, the objective of this work is to develop an application for smartphones facing the postoperative follow-up of patients undergoing robotic radical prostatectomy and compare adherence to treatment compared to accompanied by traditional way patient. in addition, we will evaluate the progress of the ipss, iciq and iief-5 compared to preoperatively in patients undergoing prostatectomy robotic radical.


Eligibility criteria:
inclusion criteria: * patients having a diagnosis of prostate cancer who are undergoing robotic radical prostatectomy for treatment of the disease and who accept to participate in the study by signing the informed consent term. exclusion criteria: * patients who refused to participate in the study